---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001105"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:20:44.855124+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025

## Summary
- Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).
- Cash and marketable securities $127M, down from $152M; cash runway into 2027.
- Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.
- Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.
- CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs.

## SEC filing metadata
- accession: 0001171843-25-001105
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/0001171843-25-001105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/f8k_022625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001105
- JSON: https://secwatch.observer/filing/0001171843-25-001105.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.